<code id='6EA1CE4E6C'></code><style id='6EA1CE4E6C'></style>
    • <acronym id='6EA1CE4E6C'></acronym>
      <center id='6EA1CE4E6C'><center id='6EA1CE4E6C'><tfoot id='6EA1CE4E6C'></tfoot></center><abbr id='6EA1CE4E6C'><dir id='6EA1CE4E6C'><tfoot id='6EA1CE4E6C'></tfoot><noframes id='6EA1CE4E6C'>

    • <optgroup id='6EA1CE4E6C'><strike id='6EA1CE4E6C'><sup id='6EA1CE4E6C'></sup></strike><code id='6EA1CE4E6C'></code></optgroup>
        1. <b id='6EA1CE4E6C'><label id='6EA1CE4E6C'><select id='6EA1CE4E6C'><dt id='6EA1CE4E6C'><span id='6EA1CE4E6C'></span></dt></select></label></b><u id='6EA1CE4E6C'></u>
          <i id='6EA1CE4E6C'><strike id='6EA1CE4E6C'><tt id='6EA1CE4E6C'><pre id='6EA1CE4E6C'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:7923
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In